For example, blocking the CD47-SIRPα pathway together with treatment with sodium stibogluconate (SSG), an antileishmaniasis drug, overcomes the resistance of anti-CD20-opsonized B-cell lymphoma cells to neutrophil killing.341 Hu5F9-G4 (now known as magrolimab) is in a phase II/III clinical study for AML and has shown a favorable safety profile in combination with azathioprine (AZA).342,343 Magrolimab in combination with AZA demonstrated early efficacy in AML patients with mutated TP53.344,345. This evidence concerns the gene TP53 and acute myeloid leukemia.